Clinical Trial 43391

share

Garden Grove, CA 92845


Study Summary:

This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.



Inclusion Criteria:

  • Patients with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • Medically stable during the six months prior to study entry
  • Outpatient with no hospitalization for worsening of schizophrenia or schizoaffective disorder within six months prior to study entry
  • PANSS negative symptom factor score of 18 or higher
  • The following rating on items of the PANSS: (a) less than 5 on G8 (uncooperativeness), P1 (delusions), P3 (hallucinations), P4 (excitement/hyperactivity), and P6 (suspiciousness/persecution); (b) less than 4 on P7 (hostility), and G14 (poor impulse control)
  • Has an informant who is considered reliable by the Investigator
  • Part B only: Stable treatment with a dopamine/serotonin (D2/5HT2A) antagonist or a D2 partial agonist for a minimum of 6 months and receiving no more than two antipsychotics


Qualified Participants May Receive:

Monetary compensation and study-related care at no cost to the participant. 


Study is Available At:

CNS - Collaborative Neuroscience
12772 Valley View St.
Garden Grove, CA 92845
View Clinic Location

 


If you or someone you care for is interested in participating in this clinical trial and lives within 50 miles of the clinic, please complete the form below and click 'I Am Interested In This Study'

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.